Haoyu Li
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Mazdutide versus placebo in Chinese adults with type 2 diabetes.
Journal: Nature
Published: June 16, 2025
Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.
Journal: Ophthalmology science
Published: February 08, 2025
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.
Journal: Cardiovascular diabetology
Published: January 21, 2025
Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized, Double-Masked, Active-Controlled, Noninferiority, Phase II Trial.
Journal: Ophthalmology. Retina
Published: December 22, 2023
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Journal: Diabetes care
Published: July 12, 2023
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.
Journal: The Lancet regional health. Western Pacific
Published: May 31, 2023
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.
Journal: JACC. Asia
Published: November 16, 2022
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
Journal: BMC medicine
Published: October 09, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026